This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should WisdomTree U.S. Total Dividend ETF (DTD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DTD
The Zacks Analyst Blog Highlights GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific
by Zacks Equity Research
GE Healthcare, Johnson & Johnson, Abbott and Boston Scientific are part of the Zacks top Analyst Blog.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
by Kinjel Shah
Both JNJ and ABBV expect their sales and profits to improve in 2025.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
by Urmimala Biswas
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
AMGN's Key Drugs Repatha, Evenity & Blincyto Drive Q1 Sales Growth
by Zacks Equity Research
AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth
by Zacks Equity Research
AMGN beats first-quarter estimates for earnings and sales. Sales of most of its products, Prolia, Xgeva, Repatha, Blincyto and Evenity beat estimates.
Is WisdomTree U.S. Total Dividend ETF (DTD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTD
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis
by Zacks Equity Research
Amazon, Johnson & Johnson, Cisco Systems and NeurAxis are included in this Analyst Blog.
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
by Zacks Equity Research
GSK reports mixed first-quarter 2025 results. Shares rise in pre-market after it reaffirms guidance and says it is "well positioned" to handle the U.S. tariffs.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
by Shaun Pruitt
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales
by Zacks Equity Research
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
GSK to Report First-Quarter Earnings: Is a Beat in Store?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
by Zacks Equity Research
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
by Sanghamitra Saha
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
by Kinjel Shah
JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.